Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
7 citations
,
July 1990 in “Journal of the American Academy of Dermatology” A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
August 2021 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
March 2026 in “Microchemical Journal” 71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” April 2026 in “Expert Opinion on Biological Therapy” Prurigo nodularis is hard to diagnose and treat, but new biologics offer hope for better management.
Lupus nephritis can cause severe kidney and blood vessel problems.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
6 citations
,
November 2018 in “American journal of transplantation” UV light helped human hair transplants survive in mice without broad immunosuppression.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
15 citations
,
June 1964 in “Experimental Biology and Medicine” Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.